{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T17:49:55Z","timestamp":1778953795980,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003693","name":"Korea Institute of Science and Technology","doi-asserted-by":"crossref","award":["2Z05630"],"award-info":[{"award-number":["2Z05630"]}],"id":[{"id":"10.13039\/501100003693","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2008-00592"],"award-info":[{"award-number":["2008-00592"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Nonalcoholic steatohepatitis (NASH), a liver disease caused by a nonalcoholic fatty liver, is increasing in incidence worldwide. Owing to the complexity of its pathogenic mechanisms, there are no therapeutic agents for this disease yet. The ideal drug for NASH needs to concurrently decrease hepatic lipid accumulation and exert anti-inflammatory, antifibrotic, and antioxidative effects in the liver. Because of their multipurpose therapeutic effects, we considered that medicinal herbs are suitable for treating patients with NASH.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We determined the efficacy of the alcoholic extract of <jats:italic>Lysimachia vulgaris<\/jats:italic> var. <jats:italic>davurica<\/jats:italic> (LV), an edible medicinal herb, for NASH treatment. For inducing NASH, C57BLKS\/J lar-Lepr<jats:sup>db<\/jats:sup>\/Lepr<jats:sup>db<\/jats:sup> (<jats:italic>db<\/jats:italic>\/<jats:italic>db<\/jats:italic>) male mice were fed with a methionine-choline deficient (MCD) diet ad libitum. After 3\u2009weeks, the LV extract and a positive control (GFT505) were administered to mice by oral gavage for 3\u2009weeks with a continued MCD diet as needed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In mice with diet-induced NASH, the LV extract could relieve the disease symptoms; that is, the extract ameliorated hepatic lipid accumulation and also showed antioxidative and anti-inflammatory effects. The LV extract also activated nuclear factor E2-related factor 2 (Nrf2) expression, leading to the upregulation of antioxidants and detoxification signaling. Moreover, the extract presented remarkable efficacy in alleviating liver fibrosis compared with GFT505. This difference was caused by significant LV extract-mediated reduction in the mRNA expression of fibrotic genes like the alpha-smooth muscle actin and collagen type 3 alpha 1. Reduction of fibrotic genes may thus relate with the downregulation of transforming growth factor beta (TGF\u03b2)\/Smad signaling by LV extract administration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Lipid accumulation and inflammatory responses in the liver were alleviated by feeding LV extract to NASH-induced mice. Moreover, the LV extract strongly prevented liver fibrosis by blocking TGF\u03b2\/Smad signaling. Hence, LV showed sufficient potency for use as a therapeutic agent against NASH.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12906-021-03212-6","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T13:06:12Z","timestamp":1611579972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Yellow loosestrife (Lysimachia vulgaris var. davurica) ameliorates liver fibrosis in db\/db mice with methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis"],"prefix":"10.1186","volume":"21","author":[{"given":"Yang-Ju","family":"Son","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da Seul","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Min","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myungsuk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyhye","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7805-0521","authenticated-orcid":false,"given":"Chu Won","family":"Nho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,25]]},"reference":[{"key":"3212_CR1","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1126\/science.1204265","volume":"332","author":"JC Cohen","year":"2011","unstructured":"Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519\u201323.","journal-title":"Science"},{"key":"3212_CR2","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","volume":"116","author":"CA Matteoni","year":"1999","unstructured":"Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastoenterology. 1999;116:1413\u20139.","journal-title":"Gastoenterology"},{"key":"3212_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1172\/JCI106255","volume":"49","author":"TG Redgrave","year":"1970","unstructured":"Redgrave TG. Formation of cholesteryl ester-rich particulate lipid during metabolism of chylomicrons. J Clin Investig. 1970;49:465\u201371.","journal-title":"J Clin Investig"},{"key":"3212_CR4","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMra011775","volume":"346","author":"P Angulo","year":"2002","unstructured":"Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221\u201331.","journal-title":"N Engl J Med"},{"key":"3212_CR5","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1002\/hep.20973","volume":"43","author":"GC Farrell","year":"2006","unstructured":"Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99\u2013112.","journal-title":"Hepatology"},{"key":"3212_CR6","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u201321.","journal-title":"Hepatology"},{"key":"3212_CR7","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.jhep.2015.02.041","volume":"62","author":"V Ratziu","year":"2015","unstructured":"Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol. 2015;62:S65\u201375.","journal-title":"J Hepatol"},{"key":"3212_CR8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.livres.2017.12.006","volume":"1","author":"W Dunn","year":"2017","unstructured":"Dunn W. Therapies for non-alcoholic steatohepatitis. Liver Res. 2017;1:214\u201320.","journal-title":"Liver Res"},{"key":"3212_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.lfs.2005.09.012","volume":"78","author":"MJ Balunas","year":"2005","unstructured":"Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci. 2005;78:431\u201341.","journal-title":"Life Sci"},{"key":"3212_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1211\/0022357011775334","volume":"53","author":"AD Kinghorn","year":"2001","unstructured":"Kinghorn AD. Pharmacognosy in the 21st century. J Pharm Pharmacol. 2001;53:135\u201348.","journal-title":"J Pharm Pharmacol"},{"key":"3212_CR11","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1556\/ABiol.64.2013.2.8","volume":"64","author":"A Turker","year":"2013","unstructured":"Turker A, Guner B. Efficient plant regeneration of yellow loosestrife (Lysimachia vulgaris L.), a medicinal plant. Acta Biol Hung. 2013;64:218\u201330.","journal-title":"Acta Biol Hung"},{"key":"3212_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.21010\/ajtcam.v14i2.19","volume":"14","author":"AB Yildrim","year":"2017","unstructured":"Yildrim AB, Guner B, Karakas FP, Turker AU. Evaluation of antibacterial, antitumor, antioxidant activities and phenolic constituents of field-grown and in vitro-grown Lysimachia vulgaris L. Afr J Tradit Complement Altern Med. 2017;14:177\u201387.","journal-title":"Afr J Tradit Complement Altern Med"},{"key":"3212_CR13","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1002\/(SICI)1099-1573(1998)12:1+<S70::AID-PTR254>3.0.CO;2-9","volume":"12","author":"I Podolak","year":"1998","unstructured":"Podolak I, Elas M, Cieszka K. In vitro antifungal and cytotoxic activity of triterpene saponosides and quinoid pigments from Lysimachia vulgaris L. Phytother Res. 1998;12:S70\u20133.","journal-title":"Phytother Res"},{"key":"3212_CR14","first-page":"175","volume-title":"Asian Functional Foods","author":"SA Lee","year":"1980","unstructured":"Lee SA. Traditional Functional Foods in Korea. In: Shi J, Ho C-T, Shahidi F, editors. Asian Functional Foods. USA: CRC Press; 1980. p. 175."},{"key":"3212_CR15","doi-asserted-by":"publisher","first-page":"12419","DOI":"10.1021\/acs.jafc.9b01488","volume":"67","author":"SY Kim","year":"2019","unstructured":"Kim SY, Lee JY, Jhin C, Shin JM, Kim M, Ahn HR, et al. Reduction of hepatic lipogenesis by loliolide and pinoresinol from Lysimachia vulgaris via degrading liver X receptors. J Agric Food Chem. 2019;67:12419\u201327.","journal-title":"J Agric Food Chem"},{"key":"3212_CR16","doi-asserted-by":"publisher","first-page":"BSR20180429","DOI":"10.1042\/BSR20180429","volume":"38","author":"JM Wang","year":"2018","unstructured":"Wang JM, Cai H, Li JH, Chen RX, Zhang YY, Li JY, et al. Detoxication mechanisms of Radix Tripterygium wilfordii via compatibility with Herba Lysimachia christinae in S180-bearing mice by involving Nrf2. Biosci Rep. 2018;38:BSR20180429.","journal-title":"Biosci Rep"},{"key":"3212_CR17","first-page":"89","volume":"6","author":"J Wang","year":"2012","unstructured":"Wang J, Zhang Y, Zhang Y, Cui Y, Liu J, Zhang B. Protective effect of Lysimachia christinae against acute alcohol-induced liver injury in mice. Biosci Trends. 2012;6:89\u201397.","journal-title":"Biosci Trends"},{"key":"3212_CR18","first-page":"1473","volume":"9","author":"A Toth","year":"2014","unstructured":"Toth A, Toth G, Kery A. Polyphenol composition and antioxidant capacity of three Lysimachia species. Nat Prod Commun. 2014;9:1473\u20138.","journal-title":"Nat Prod Commun"},{"key":"3212_CR19","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1194\/jlr.M800042-JLR200","volume":"49","author":"ME Rinella","year":"2008","unstructured":"Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, Green RM. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline=deficient diet. J Lipid Res. 2008;49:1068\u201376.","journal-title":"J Lipid Res"},{"key":"3212_CR20","doi-asserted-by":"publisher","first-page":"G1035","DOI":"10.1152\/ajpgi.00199.2004","volume":"287","author":"A Sahai","year":"2004","unstructured":"Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM, et al. Obese and diabetic db\/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol- Gastr L. 2004;287:G1035\u201343.","journal-title":"Am J Physiol- Gastr L"},{"key":"3212_CR21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1051\/rnd:19960404","volume":"36","author":"D Gruffat","year":"1996","unstructured":"Gruffat D, Durand D, Graulet B, Bauchart D. Regulation of VLDL synthesis and secretion in the liver. Reprod Nutr Dev. 1996;36:375\u201389.","journal-title":"Reprod Nutr Dev"},{"key":"3212_CR22","doi-asserted-by":"publisher","first-page":"e0132315","DOI":"10.1371\/journal.pone.0132315","volume":"10","author":"MV Machado","year":"2015","unstructured":"Machado MV, Michelotti GA, Xie G, de Almeida TP, Boursier J, Bohnic B, et al. Correction: mouse models of diet-induced nonalcoholic Steatohepatitis reproduce the heterogeneity of the human disease. PLoS One. 2015;10:e0132315.","journal-title":"PLoS One"},{"key":"3212_CR23","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1111\/j.1440-1746.2008.05543.x","volume":"23","author":"CZ Larter","year":"2008","unstructured":"Larter CZ, Yeh MM. Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol. 2008;23:1635\u201348.","journal-title":"J Gastroenterol Hepatol"},{"key":"3212_CR24","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.2337\/dc11-0093","volume":"34","author":"B Cariou","year":"2011","unstructured":"Cariou B, Zair Y, Staels B, Bruckert E. Effects of the new dual PPAR alpha\/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care. 2011;34:2008\u201314.","journal-title":"Diabetes Care"},{"key":"3212_CR25","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.semcdb.2012.01.003","volume":"23","author":"L Poulsen","year":"2012","unstructured":"Poulsen L, Siersbaek M, Mandrup S. PPARs: fatty acid sensors controlling metabolism. Semin Cell Dev Biol. 2012;23:631\u20139.","journal-title":"Semin Cell Dev Biol"},{"key":"3212_CR26","doi-asserted-by":"publisher","first-page":"13291","DOI":"10.1074\/jbc.R900010200","volume":"284","author":"T Nguyen","year":"2009","unstructured":"Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem. 2009;284:13291\u20135.","journal-title":"J Biol Chem"},{"key":"3212_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1006\/bbrc.1997.6943","volume":"236","author":"K Itoh","year":"1997","unstructured":"Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, et al. An Nrf2\/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 1997;236:313\u201322.","journal-title":"Biochem Biophys Res Commun"},{"key":"3212_CR28","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.molmed.2004.09.003","volume":"10","author":"H Motohashi","year":"2004","unstructured":"Motohashi H, Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med. 2004;10:549\u201357.","journal-title":"Trends Mol Med"},{"key":"3212_CR29","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1007\/s00018-016-2223-0","volume":"73","author":"A Loboda","year":"2016","unstructured":"Loboda A, Damulewicz M, Pyza E, Al J, Dulak J. Role of Nrf2\/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism. Cell Mol Life Sci. 2016;73:3221\u201347.","journal-title":"Cell Mol Life Sci"},{"key":"3212_CR30","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1089\/ars.2005.7.1664","volume":"7","author":"KW Kang","year":"2005","unstructured":"Kang KW, Lee SJ, Kim SG. Molecular mechanism of nrf2 activation by oxidative stress. Antioxid Redox Signal. 2005;7:1664\u201373.","journal-title":"Antioxid Redox Signal"},{"key":"3212_CR31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.taap.2012.05.010","volume":"262","author":"KC Wu","year":"2012","unstructured":"Wu KC, Liu J, Klaassen CD. Role of Nrf2 in preventing ethanol-induced oxidative stress and lipid accumulation. Toxicol Appl Pharmacol. 2012;262:321\u20139.","journal-title":"Toxicol Appl Pharmacol"},{"key":"3212_CR32","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/j.clinre.2015.06.015","volume":"39","author":"M Sun","year":"2015","unstructured":"Sun M, Kisseleva T. Reversibility of liver fibrosis. Clin Res Hepatol Gastroenterol. 2015;39:S60\u20133.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"3212_CR33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1152\/physrev.00013.2007","volume":"88","author":"SL Friedman","year":"2008","unstructured":"Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88:125\u201372.","journal-title":"Physiol Rev"},{"key":"3212_CR34","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.jhep.2016.01.010","volume":"64","author":"I Lua","year":"2016","unstructured":"Lua I, Li Y, Zagory JA, Wang KS, French SW, S\u00e9vigny J, Asahina K. Characterization of hepatic stellate cells, portal fibroblasts, and mesothelial cells in normal and fibrotic livers. J Hepatol. 2016;64:1137\u201346.","journal-title":"J Hepatol"},{"key":"3212_CR35","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.dld.2004.11.009","volume":"37","author":"G Carpino","year":"2005","unstructured":"Carpino G, Morini S, Corradini SG, Franchitto A, Merli M, Siciliano M, et al. Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig Liver Dis. 2005;37:349\u201356.","journal-title":"Dig Liver Dis"},{"key":"3212_CR36","first-page":"7","volume":"4","author":"S Cherng","year":"2008","unstructured":"Cherng S, Young J, Ma H. Alpha-smooth muscle actin (\u03b1-SMA). J Am Sci. 2008;4:7\u20139.","journal-title":"J Am Sci"},{"key":"3212_CR37","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1136\/gut.2005.071118","volume":"55","author":"K Tomita","year":"2006","unstructured":"Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, et al. Tumour necrosis factor a signaling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut. 2006;55:415\u201324.","journal-title":"Gut"},{"key":"3212_CR38","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/labinvest.2010.123","volume":"90","author":"C Liu","year":"2010","unstructured":"Liu C, Tao Q, Sun M, Wu JZ, Yang W, Jian P, et al. Kupffer cells are associated with apoptosis, inflammation and fibrotic effects in hepatic fibrosis in rats. Lab Investig. 2010;90:1805\u20136.","journal-title":"Lab Investig"},{"key":"3212_CR39","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1053\/j.gastro.2009.04.011","volume":"137","author":"J Wang","year":"2009","unstructured":"Wang J, Leclercq I, Brymora JM, Xu N, Ramezani-Moghadam M, London RM. Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterol. 2009;137:713\u201323.","journal-title":"Gastroenterol"},{"key":"3212_CR40","doi-asserted-by":"publisher","first-page":"e31350","DOI":"10.1371\/journal.pone.0031350","volume":"7","author":"LX Tang","year":"2012","unstructured":"Tang LX, He RH, Yang G, Tan JJ, Li Z, Meng XM, et al. Asiatic acid inhibits liver fibrosis by blocking TGF-beta\/Smad Signaling in vivo and in vitro. PLoS One. 2012;7:e31350.","journal-title":"PLoS One"},{"key":"3212_CR41","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/gut.2005.088690","volume":"56","author":"Y Inagaki","year":"2007","unstructured":"Inagaki Y, Okazaki I. Emerging insights into transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut. 2007;56:284\u201392.","journal-title":"Gut."},{"key":"3212_CR42","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3389\/fphys.2015.00082","volume":"6","author":"XM Meng","year":"2015","unstructured":"Meng XM, Tang PM, Li J, Lan HY. TGF- \u03b2\/Smad signaling in renal fibrosis. Front Physiol. 2015;6:82.","journal-title":"Front Physiol"},{"key":"3212_CR43","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/08977194.2011.595714","volume":"29","author":"A Biernacka","year":"2011","unstructured":"Biernacka A, Dobaczewski M, Frangogiannis NG. TGF-\u03b2 signaling in fibrosis. Growth Factors. 2011;29:196\u2013202.","journal-title":"Growth Factors"},{"key":"3212_CR44","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1161\/01.ATV.0000225777.58488.f2","volume":"26","author":"M Wang","year":"2006","unstructured":"Wang M, Zhao D, Spinetti G, Zhang J, Jiang LQ, Pintus G, et al. Matrix metalloproteinase 2 activation of transforming growth factor-\u03b21 (TGF-\u03b21) and TGF-\u03b21-type II receptor signaling within the aged arterial wall. Arterioscl Throm Vas. 2006;26:1503\u20139.","journal-title":"Arterioscl Throm Vas"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-021-03212-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12906-021-03212-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-021-03212-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T13:07:52Z","timestamp":1611580072000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-021-03212-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,25]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3212"],"URL":"https:\/\/doi.org\/10.1186\/s12906-021-03212-6","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,25]]},"assertion":[{"value":"19 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}